Sera Prognostics (NASDAQ:SERA) Rating Increased to Hold at Wall Street Zen

Sera Prognostics (NASDAQ:SERA - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Saturday.

Sera Prognostics Stock Performance

Sera Prognostics stock opened at $1.92 on Friday. The business's 50-day simple moving average is $2.32 and its two-hundred day simple moving average is $4.46. The company has a market cap of $72.33 million, a PE ratio of -2.04 and a beta of 0.71. Sera Prognostics has a fifty-two week low of $1.37 and a fifty-two week high of $9.13.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Sera Prognostics had a negative return on equity of 51.35% and a negative net margin of 28,685.22%. The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.06 million. As a group, analysts predict that Sera Prognostics will post -0.96 EPS for the current fiscal year.

Insider Transactions at Sera Prognostics

In related news, CEO Zhenya Lindgardt sold 23,042 shares of the company's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $1.43, for a total value of $32,950.06. Following the completion of the transaction, the chief executive officer now owns 844,209 shares of the company's stock, valued at approximately $1,207,218.87. This represents a 2.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold 67,721 shares of company stock worth $127,856 over the last quarter. 13.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Sera Prognostics

Large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets acquired a new position in Sera Prognostics in the 4th quarter worth about $28,000. XTX Topco Ltd acquired a new position in Sera Prognostics in the 1st quarter worth about $39,000. Price T Rowe Associates Inc. MD acquired a new position in Sera Prognostics in the 4th quarter worth about $93,000. Gotham Asset Management LLC acquired a new position in Sera Prognostics in the 4th quarter worth about $96,000. Finally, Walleye Capital LLC acquired a new position in Sera Prognostics in the 4th quarter worth about $98,000. Institutional investors and hedge funds own 54.64% of the company's stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.